

Susan P Mollan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5417688/publications.pdf>

Version: 2024-02-01

123
papers

4,411
citations

126858

33
h-index

123376

61
g-index

133
all docs

133
docs citations

133
times ranked

2506
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.5	667
2	Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. <i>Lancet Neurology</i> , The, 2016, 15, 78-91.	4.9	321
3	Idiopathic intracranial hypertension: consensus guidelines on management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1088-1100.	0.9	303
4	Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 982-992.	0.9	173
5	The expanding burden of idiopathic intracranial hypertension. <i>Eye</i> , 2019, 33, 478-485.	1.1	148
6	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	0.9	128
7	European Headache Federation guideline on idiopathic intracranial hypertension. <i>Journal of Headache and Pain</i> , 2018, 19, 93.	2.5	111
8	Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension. <i>JAMA Neurology</i> , 2021, 78, 678.	4.5	86
9	Headache determines quality of life in idiopathic intracranial hypertension. <i>Journal of Headache and Pain</i> , 2015, 16, 521.	2.5	79
10	Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom. <i>JAMA Neurology</i> , 2019, 76, 1088.	4.5	79
11	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
12	Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 522-530.	0.4	78
13	A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension. <i>Practical Neurology</i> , 2014, 14, 380-390.	0.5	76
14	Postcataract endophthalmitis: Incidence and microbial isolates in a United Kingdom region from 1996 through 2004. <i>Journal of Cataract and Refractive Surgery</i> , 2007, 33, 265-268.	0.7	68
15	Accuracy of Goldmann, ocular response analyser, Pascal and TonoPen XL tonometry in keratoconic and normal eyes. <i>British Journal of Ophthalmology</i> , 2008, 92, 1661-1665.	2.1	66
16	Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol. <i>BMJ Open</i> , 2017, 7, e017426.	0.8	63
17	Advances in the understanding of headache in idiopathic intracranial hypertension. <i>Current Opinion in Neurology</i> , 2019, 32, 92-98.	1.8	61
18	Aetiology and outcomes of adult superior oblique palsies: a modern series. <i>Eye</i> , 2009, 23, 640-644.	1.1	56

#	ARTICLE	IF	CITATIONS
19	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	0.9	56
20	A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. <i>JCI Insight</i> , 2019, 4, .	2.3	55
21	A new era for giant cell arteritis. <i>Eye</i> , 2020, 34, 1013-1026.	1.1	53
22	Therapeutic lumbar puncture for headache in idiopathic intracranial hypertension: Minimal gain, is it worth the pain?. <i>Cephalalgia</i> , 2019, 39, 245-253.	1.8	51
23	Idiopathic Intracranial Hypertension Associated with Iron Deficiency Anaemia: A Lesson for Management. <i>European Neurology</i> , 2009, 62, 105-108.	0.6	50
24	What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. <i>BMJ Open</i> , 2019, 9, e026573.	0.8	48
25	11 β -Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. <i>Brain Communications</i> , 2020, 2, fcz050.	1.5	46
26	Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. <i>JAMA Neurology</i> , 2020, 77, 1514.	4.5	45
27	Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. <i>JCI Insight</i> , 2021, 6, .	2.3	45
28	Using Optical Coherence Tomography as a Surrogate of Measurements of Intracranial Pressure in Idiopathic Intracranial Hypertension. <i>JAMA Ophthalmology</i> , 2020, 138, 1264.	1.4	43
29	Evaluating the Fat Distribution in Idiopathic Intracranial Hypertension Using Dual-Energy X-ray Absorptiometry Scanning. <i>Neuro-Ophthalmology</i> , 2018, 42, 99-104.	0.4	42
30	<p><p>Exploring The Current Management Idiopathic Intracranial Hypertension, And Understanding The Role Of Dural Venous Sinus Stenting</p></p>. <i>Eye and Brain</i> , 2020, Volume 12, 1-13.	3.8	40
31	11 β HSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 174-187.	1.8	39
32	Evaluation and management of adult idiopathic intracranial hypertension. <i>Practical Neurology</i> , 2018, 18, 485-488.	0.5	38
33	The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension. <i>Neurology: Clinical Practice</i> , 2021, 11, e504-e507.	0.8	38
34	Characterising the patient experience of diagnostic lumbar puncture in idiopathic intracranial hypertension: a cross-sectional online survey. <i>BMJ Open</i> , 2018, 8, e020445.	0.8	37
35	Idiopathic Intracranial Hypertension: Evaluation of Admissions and Emergency Readmissions through the Hospital Episode Statistic Dataset between 2002â€”2020. <i>Life</i> , 2021, 11, 417.	1.1	37
36	Headache attributed to idiopathic intracranial hypertension and persistent postâ€”idiopathic intracranial hypertension headache: A narrative review. <i>Headache</i> , 2021, 61, 808-816.	1.8	37

#	ARTICLE	IF	CITATIONS
37	What Do Transgender Patients Teach Us About Idiopathic Intracranial Hypertension?. <i>Neuro-Ophthalmology</i> , 2017, 41, 326-329.	0.4	35
38	Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension. <i>Journal of Headache and Pain</i> , 2021, 22, 118.	2.5	33
39	Raised intracranial pressure in those presenting with headache. <i>BMJ: British Medical Journal</i> , 2018, 363, k3252.	2.4	31
40	European Headache Federation recommendations for neurologists managing giant cell arteritis. <i>Journal of Headache and Pain</i> , 2020, 21, 28.	2.5	31
41	Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation. <i>Headache</i> , 2021, 61, 157-169.	1.8	31
42	Idiopathic intracranial hypertension: Update on diagnosis and management. <i>Clinical Medicine</i> , 2020, 20, 384-388.	0.8	29
43	Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 795-797.	0.9	28
44	Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension. <i>Current Opinion in Neurology</i> , 2019, 32, 422-431.	1.8	27
45	Emerging themes in idiopathic intracranial hypertension. <i>Journal of Neurology</i> , 2020, 267, 3776-3784.	1.8	27
46	Aspirin as adjunctive treatment for giant cell arteritis. <i>The Cochrane Library</i> , 2014, , CD010453.	1.5	26
47	Cognitive performance in idiopathic intracranial hypertension and relevance of intracranial pressure. <i>Brain Communications</i> , 2021, 3, fcab202.	1.5	26
48	Reviewing the Recent Developments in Idiopathic Intracranial Hypertension. <i>Ophthalmology and Therapy</i> , 2020, 9, 767-781.	1.0	25
49	Segmentation error in spectral domain optical coherence tomography measures of the retinal nerve fibre layer thickness in idiopathic intracranial hypertension. <i>BMC Ophthalmology</i> , 2017, 17, 257.	0.6	24
50	Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. <i>Journal of Headache and Pain</i> , 2020, 21, 116.	2.5	24
51	Does use of isotretinoin rule out a career in flying?. <i>British Journal of Ophthalmology</i> , 2006, 90, 957-959.	2.1	23
52	New horizons for idiopathic intracranial hypertension: advances and challenges. <i>British Medical Bulletin</i> , 2020, 136, 118-126.	2.7	23
53	Reviewing the Pathophysiology Behind the Advances in the Management of Giant Cell Arteritis. <i>Ophthalmology and Therapy</i> , 2019, 8, 177-193.	1.0	22
54	Association of Amount of Weight Lost After Bariatric Surgery With Intracranial Pressure in Women With Idiopathic Intracranial Hypertension. <i>Neurology</i> , 2022, 99, .	1.5	22

#	ARTICLE	IF	CITATIONS
55	Optical coherence tomography (OCT) in unconscious and systemically unwell patients using a mobile OCT device: a pilot study. <i>BMJ Open</i> , 2019, 9, e030882.	0.8	20
56	Mitomycin C in the treatment of a Schneiderian (inverted) papilloma of the lacrimal sac. <i>International Ophthalmology</i> , 2010, 30, 303-305.	0.6	19
57	Development and validation of a questionnaire assessing the quality of life impact of Colour Blindness (CBQoL). <i>BMC Ophthalmology</i> , 2017, 17, 179.	0.6	19
58	Incidence of endophthalmitis following vitreoretinal surgery. <i>International Ophthalmology</i> , 2009, 29, 203-205.	0.6	18
59	Cranial ultrasound for the diagnosis of giant cell arteritis. A retrospective cohort study. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2015, 45, 268-272.	0.2	18
60	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology, The</i> , 2021, 3, e71-e82.	2.2	18
61	Giant cell arteritis: new concepts, treatments and the unmet need that remains. <i>Rheumatology</i> , 2019, 58, 1123-1125.	0.9	17
62	Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT). <i>Journal of Neurology</i> , 2022, 269, 1945-1956.	1.8	17
63	Managing idiopathic intracranial hypertension in pregnancy: practical advice. <i>Practical Neurology</i> , 2022, 22, 295-300.	0.5	17
64	Idiopathic intracranial hypertension: Evaluation of births and fertility through the Hospital Episode Statistics dataset. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 2019-2027.	1.1	17
65	The Utility of Fundus Fluorescein Angiography in Neuro-Ophthalmology. <i>Neuro-Ophthalmology</i> , 2019, 43, 217-234.	0.4	16
66	Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002-13, without a decrease in associated sight loss: potential implications for service provision. <i>Rheumatology</i> , 2015, 54, 375-377.	0.9	15
67	Cost-effectiveness of bariatric surgery versus community weight management to treat obesity-related idiopathic intracranial hypertension: evidence from a single-payer healthcare system. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 1310-1316.	1.0	15
68	The Ocular Glymphatic System and Idiopathic Intracranial Hypertension: Author Response to "Hypodense Holes and the Ocular Glymphatic System", 2017, 58, 1134.		14
69	The Role of Metabolism in Migraine Pathophysiology and Susceptibility. <i>Life</i> , 2021, 11, 415.	1.1	14
70	Outcomes measures in idiopathic intracranial hypertension. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 687-700.	1.4	12
71	Differing presenting features of idiopathic intracranial hypertension in the UK and US. <i>Eye</i> , 2019, 33, 1014-1019.	1.1	11
72	Increased systemic and adipose 11 β -HSD1 activity in idiopathic intracranial hypertension. <i>European Journal of Endocrinology</i> , 2022, 187, 323-333.	1.9	11

#	ARTICLE	IF	CITATIONS
73	Sight-threatening pseudotumour cerebri associated with excess vitamin A supplementation. <i>Practical Neurology</i> , 2015, 15, 72-73.	0.5	10
74	Photopsia. <i>Practical Neurology</i> , 2020, 20, 415-419.	0.5	10
75	Current Perspectives on Idiopathic Intracranial Hypertension without Papilloedema. <i>Life</i> , 2021, 11, 472.	1.1	10
76	Profile of tocilizumab and its potential in the treatment of giant cell arteritis. <i>Eye and Brain</i> , 2018, Volume 10, 1-11.	3.8	9
77	Do Optic Canal Dimensions Measured on CT Influence the Degree of Papilloedema and Visual Dysfunction in Idiopathic Intracranial Hypertension?. <i>Neuro-Ophthalmology</i> , 2019, 43, 3-9.	0.4	9
78	Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension. <i>Eye</i> , 2020, 34, 1321-1333.	1.1	9
79	The use of transdermal optical coherence tomography to image the superficial temporal arteries. <i>Eye</i> , 2017, 31, 157-160.	1.1	8
80	Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. <i>BMJ Case Reports</i> , 2019, 12, e229236.	0.2	8
81	Vogt-Koyanagi-Harada disease. <i>Practical Neurology</i> , 2019, 19, 364-367.	0.5	8
82	Enlarged and Enhancing Optic Nerves in Advanced Glial Fibrillary Acidic Protein Meningoencephalomyelitis. <i>Journal of Neuro-Ophthalmology</i> , 2019, 39, 411-415.	0.4	8
83	Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: reply. <i>Rheumatology</i> , 2020, 59, e163-e164.	0.9	8
84	Cerebrospinal fluid shunting protocol for idiopathic intracranial hypertension for an improved revision rate. <i>Journal of Neurosurgery</i> , 2022, 136, 1790-1795.	0.9	8
85	Intracranial dermoid cyst presenting as an isolated fourth nerve palsy. <i>Journal of Neurology</i> , 2009, 256, 820-821.	1.8	7
86	Idiopathic Intracranial Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1059.	3.8	7
87	Headache for ophthalmologists: current advances in headache understanding and management. <i>Eye</i> , 2021, 35, 1574-1586.	1.1	7
88	Optical coherence tomography confirms shunt malfunction and recurrence of raised intracranial pressure in optic atrophy. <i>British Journal of Neurosurgery</i> , 2022, 36, 185-191.	0.4	6
89	Telemetric monitoring in idiopathic intracranial hypertension demonstrates intracranial pressure in a case with sight-threatening disease. <i>Acta Neurochirurgica</i> , 2021, 163, 725-731.	0.9	6
90	The Health Economic Evaluation of Bariatric Surgery Versus a Community Weight Management Intervention Analysis from the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT). <i>Life</i> , 2021, 11, 409.	1.1	6

#	ARTICLE	IF	CITATIONS
91	Tip of the iceberg in idiopathic intracranial hypertension. <i>Practical Neurology</i> , 2019, 19, 178-179.	0.5	5
92	Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines. <i>Eye</i> , 2021, 35, 699-701.	1.1	5
93	Current Perspective on Retinal Migraine. <i>Vision (Switzerland)</i> , 2021, 5, 38.	0.5	5
94	Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report. <i>British Journal of Ophthalmology</i> , 2023, 107, 267-274.	2.1	5
95	“IIH Pressure” a randomised, controlled, double blind physiology study of the effect of Exenatide on intracranial pressure. <i>BMJ Military Health</i> , 2021, 167, e1.2-e1.	0.4	4
96	British Society for Rheumatology guideline for diagnosis and treatment of giant cell arteritis. <i>Practical Neurology</i> , 2020, 20, 474-475.	0.5	3
97	Current advances in giant cell arteritis. <i>Current Opinion in Neurology</i> , 2021, 34, 133-141.	1.8	3
98	Evolving Evidence in Idiopathic Intracranial Hypertension. <i>Life</i> , 2021, 11, 1225.	1.1	3
99	Treating Idiopathic Intracranial Hypertension. <i>JAMA Neurology</i> , 2014, 71, 1326.	4.5	2
100	An update on the clinical approach to giant cell arteritis. <i>Clinical Medicine</i> , 2022, 22, 107-111.	0.8	2
101	INTERDISCIPLINARY CONSENSUS ON THE MANAGEMENT OF IIH IN THE UK. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, e1.159-e1.	0.9	1
102	A giant escape. <i>Postgraduate Medical Journal</i> , 2019, 95, 346-346.	0.9	1
103	Eosinophilic Granulomatosis with Polyangiitis Presenting as Unilateral Acute Anterior Ischaemic Optic Neuropathy. <i>Neuro-Ophthalmology</i> , 2021, 45, 109-116.	0.4	1
104	Loss of vision. , 2018, , .		1
105	One Eye or Two: Statistical Considerations in Ophthalmology With a Focus on Interventional Clinical Trials. <i>Journal of Neuro-Ophthalmology</i> , 2021, 41, 421-423.	0.4	1
106	“Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A121.2-A121.	0.9	1
107	A Transilluminating Scleral Lesion. <i>JAMA Ophthalmology</i> , 2006, 124, 1504.	2.6	0
108	United Kingdom CSF Disorders Day, 14th October 2016, University Hospitals Birmingham. <i>Neuro-Ophthalmology</i> , 2017, 41, 161-163.	0.4	0

#	ARTICLE	IF	CITATIONS
109	WED 097â€¦Diagnostic lumbar punctures in IHH: what is the patient experience?. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A10.2-A10.	0.9	0
110	United Kingdom CSF Disorders Day 2017. Neuro-Ophthalmology, 2018, 42, 414-417.	0.4	0
111	United Kingdom CSF Disorders Day 2018. Neuro-Ophthalmology, 2019, 43, 131-134.	0.4	0
112	Response to â€œComment on: â€œA new era for giant cell arteritisâ€™â€™. Eye, 2020, 34, 1929-1930.	1.1	0
113	The United Kingdom Neuro-Ophthalmology Superheroes Day 2019. Neuro-Ophthalmology, 2020, 44, 60-62.	0.4	0
114	Idiopathic Intracranial Hypertension and Anemia: A Matched Caseâ€œControl Study. Journal of Neuro-Ophthalmology, 2021, 41, e272-e273.	0.4	0
115	The red eye. , 2018, , .		0
116	Response to â€œMagnetic resonance or computed tomography venography in the evaluation of young overweight women with papilledemaâ€• Eye, 2021, 35, 3453-3454.	1.1	0
117	Teaching NeuroImages: Distinguishing Papilledema From Pseudopapilledema Using Optical Coherence Tomography. Neurology, 2021, 96, e2666-e2667.	1.5	0
118	Dr Gordon Plantâ€™s Festschrift Tidings. Neuro-Ophthalmology, 2022, 46, 1-7.	0.4	0
119	210â€¦ Erenumab for the treatment of chronic migraine with idiopathic intracranial hypertension in ocular remission. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A74.1-A74.	0.9	0
120	060â€¦ Calcitonin gene-related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A119.2-A119.	0.9	0
121	053â€¦ Intracranial pressure determines headache morbidity in idiopathic intracranial hypertension. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A117.1-A117.	0.9	0
122	052â€¦ How much weight loss is required to reduce intracranial pressure in idiopathic intracranial hypertension?. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A116.4-A117.	0.9	0
123	Bariatric surgery versus community weight management intervention for idiopathic intracranial hypertension: a randomised controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A98.1-A98.	0.9	0